~~<i id='332ED812DA'><strike id='332ED812DA'><tt id='332ED812DA'><pre id='332ED812DA'></pre></tt></strike></i>~~

Home» focus» Wikipedia

Wikipedia

author：comprehensive 2025-09-30 04:15:49 Page View：9497

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： White House calls on federal agencies to crack down on AI abuses
Next article： Anesthesiologist group: stop taking Ozempic before surgery

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Living organ donors deserve priority status for transplants

AkidneydonorwatchesasaconsentformissignedbyawitnessbeforeakidneytransplantoperationatJohnsHopkinsHos

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Excited delirium, Elijah McClain, and emergency physicians

Theterm“exciteddelirium”hasbeenusedforyearsbylawenforcementandotherfirstresponders,includinghealthca